In Vitro Diagnostics (IVD) in for rough ride in US
This article was originally published in Clinica
Executive Summary
US IVD manufacturers can expect a tough market in the short term, delegates at a HIMA meeting on November 8th and 9th were warned. The consensus of speakers at the meeting on regulatory and reimbursement issues affecting the in vitro diagnostic industry was that the market will become even more competitive as payers try to lower healthcare costs.